Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Shanghai 24 Beijing 19 Guangzhou 13 Hangzhou 12 Harbin 8
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai24 Beijing19 Guangzhou13 Hangzhou12 Harbin8
All 36 locations
Target enrolment
to

Trials with a site in Shanghai

24 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Akeso
Phase 1
243
Harbin, Shanghai, Chengdu
2026-09-30
Not yet open
Akeso
Phase 2
75
Shanghai
2026-08-10
Recruiting
Akeso
Phase 2
200
Shanghai
2026-07-17
Recruiting
Akeso
Phase 1/2
265
Shanghai
2026-07-07
Not yet open
Akeso
Phase 2
132
Shanghai
2026-06-22
Not yet open
Akeso
Phase 2
160
Guangzhou, Shanghai
2026-02-28
Recruiting
A Study of Ivonescimab in First-Line ES-SCLC
NCT07245446Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Akeso
Phase 2
180
Beijing, Xi'an, Shanghai
2025-10-29
Recruiting
Akeso
Phase 2
160
Shanghai, Tianjin
2025-09-19
Recruiting
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
Not yet open
Akeso
Phase 1
60
Shanghai
2025-07-22
Recruiting
Akeso
Phase 3
536
Shanghai
2025-07-08
Recruiting
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Not yet open
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NCT06860789Chemotherapy-induced Peripheral Neuropathy (CIPN)
Akeso
Phase 1
85
Guangzhou, Shanghai
2025-02-28
Not yet open
Akeso
Phase 1
87
Shanghai
2024-12
Recruiting
Akeso
Phase 2
172
Shanghai
2024-11-12
Active, closed
Akeso
Phase 3
682
Harbin, Shanghai
2024-10-20
Active, closed
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
NCT05840016Advanced Squamous Non Small Cell Lung Cancer
Akeso
Phase 3
532
Shanghai
2023-08-17
Active, closed
Akeso
Phase 1/2
233
Hangzhou, Shanghai
2023-07-13
Recruiting
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Akeso
Phase 3
570
Shanghai
2023-01-05
Active, closed
AK112 in Advanced Non-Small Cell Lung Cancer
NCT05499390Advanced Non-small-cell Lung Cancer
Akeso
Phase 3
398
Shanghai
2022-11-09
Active, closed
Akeso
Phase 3
636
Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2022-06-21
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

12 of the 24 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 24 studies
PhaseStudiesRecruitingShare
Phase 310541.7%
Phase 28533.3%
Phase 14116.7%
Phase 1/2218.3%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Akeso2412
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.